| 操斌全,胡星星,盛 洁,张 涵,刘瑾春.硫酸氢氯吡格雷联合瑞舒伐他汀对冠心病患者心功能、凝血功能及血液流变学的影响[J].现代生物医学进展英文版,2021,(18):3511-3514. |
| 硫酸氢氯吡格雷联合瑞舒伐他汀对冠心病患者心功能、凝血功能及血液流变学的影响 |
| Effects of Clopidogrel Bisulfate Combined with Rosuvastatin on Cardiac Function, Coagulation Function and Hemorheology in Patients with Coronary Heart Disease |
| Received:January 21, 2021 Revised:February 16, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.18.024 |
| 中文关键词: 硫酸氢氯吡格雷 瑞舒伐他汀 冠心病 心功能 凝血功能 血液流变学 血脂 |
| 英文关键词: Clopidogrel bisulfate Rosuvastatin Coronary heart disease Cardiac function Coagulation function Hemorheology Blood lipid |
| 基金项目:安徽省卫生计生委科研计划项目（2016RK059） |
|
| Hits: 716 |
| Download times: 493 |
| 中文摘要: |
| 摘要 目的：探讨硫酸氢氯吡格雷联合瑞舒伐他汀对冠心病患者凝血功能、血液流变学的影响。方法：纳入我院2018年2月～2020年6月期间收治的冠心病患者100例，根据信封抽签法分为对照组和观察组，各50例，对照组给予硫酸氢氯吡格雷联合阿托伐他汀治疗，观察组给予硫酸氢氯吡格雷联合瑞舒伐他汀治疗，疗程均为2个月。对比两组疗效、心功能、凝血功能、血液流变学、血脂，记录治疗期间两组不良反应发生情况。结果：观察组的临床总有效率高于对照组（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。治疗2个月后，观察组左心室射血分数（LVEF）高于对照组，室壁运动评分指数（WMSI）低于对照组（P<0.05）。治疗2个月后，观察组纤维蛋白原（FIB）低于对照组，活化的部分凝血酶时间（APTT）、凝血酶原时间（PT）高于对照组（P<0.05）。治疗2个月后，观察组血小板聚集、全血黏度、血浆黏度低于对照组（P<0.05）。治疗2个月后，观察组总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）水平低于对照组，高密度脂蛋白胆固醇（HDL-C）水平高于对照组（P<0.05）。结论：硫酸氢氯吡格雷联合瑞舒伐他汀治疗冠心病患者，可有效改善患者凝血功能、血脂、心功能、血液流变学，安全有效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of clopidogrel bisulfate combined with rosuvastatin on coagulation function and hemorheology in patients with coronary heart disease. Methods: 100 patients with coronary heart disease who were admitted to our hospital from February 2018 to June 2020 were selected, they were divided into control group and observation group according to envelope drawing method, 50 cases in each group. The control group was treated with clopidogrel bisulfate combined with atorvastatin, and the observation group was treated with rosuvastatin on the basis of the control group. The course of treatment was 2 months. The curative effect, cardiac function, coagulation function and hemorheology of the two groups were compared, and the incidence of adverse reactions during the treatment was recorded. Results: The total effective rate of the observation group was higher than that of the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). 2 months after treatment, the left ventricular ejection fraction (LVEF) of the observation group was higher than that of the control group, and the ventricular wall motion score index (WMSI) was lower than that of the control group (P<0.05). 2 months after treatment, fibrinogen (FIB) in the observation group was lower than that in the control group, and the activated partial thromboplastin time (APTT) and prothrombin time(PT) in the observation group were higher than those in the control group(P<0.05). 2 months after treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in the observation group were lower than those in the control group, and the level of high density lipoprotein cholesterol(HDL-C) in the observation group was higher than that in the control group (P<0.05). Conclusion: Clopidogrel bisulfate combined with rosuvastatin in the treatment of coronary heart disease patients, can effectively improve the coagulation function, cardiac function, hemorheology, safe and effective. |
|
View Full Text
View/Add Comment Download reader |
| Close |
